BioAtla Investor Presentation Deck
CAB-AXL (BA3011) Phase 2 Potentially Registrational UPS Study Design
• UPS Phase 2, part 2 potentially registrational study
-
-
Enrolling total of ~80 AXL-expressing UPS patients in Phase 2, part 2
o FDA supportive of investigating a more frequent dosing regimen (3Q4W 44% and 2Q3W 38% increased exposure over Q2W)
o First 40 patients with a TmPS >=50% will be randomized 1:1 to 3Q4W or 2Q3W dosing regimen
O
o Additional 40 patients to be enrolled at the selected dose
Primary efficacy endpoint is objective response rate (ORR) per RECIST v1.1
o Primary efficacy analysis will be based on ~60 patients treated at the selected dosing regimen
Prior systemic regimens limited to ≤3
bicatla
UPS = Undifferentiated Pleomorphic Sarcoma; LMS = Leiomyosarcoma
BioAtla| Overview 28View entire presentation